Acute Kidney Injury Medical Services in China

Acute Kidney Injury (AKI) is a sudden, often reversible decline in kidney function characterized by an abrupt increase in serum creatinine, decrease in urine output, or both—typically occurring within hours to days. It reflects a spectrum of renal dysfunction ranging from mild tubular injury to severe cortical necrosis and is classified into three stages (Stage 1–3) per the KDIGO (Kidney Disease: Improving Global Outcomes) criteria based on magnitude of creatinine rise and/or urine volume reduction. Pathogenically, AKI arises from three broad mechanisms: prerenal (e.g., hypovolemia, heart failure, sepsis-induced hypoperfusion), intrinsic renal (e.g., acute tubular necrosis from ischemia or nephrotoxins like contrast media, aminoglycosides, NSAIDs, or glomerulonephritis), and postrenal (e.g., urinary tract obstruction from stones, tumors, or prostatic hypertrophy). Cellular injury triggers inflammatory cascades, mitochondrial dysfunction, endothelial activation, and microvascular congestion—culminating in impaired glomerular filtration and tubular transport. Epidemiologically, AKI affects approximately 10–15% of all hospitalized patients globally, with incidence soaring to 30–50% in intensive care units. In China, population-based studies estimate an annual incidence of 2,800–4,200 cases per million adults, disproportionately impacting older adults (>65 years), those with preexisting chronic kidney disease (CKD), diabetes, hypertension, or cardiovascular disease. Key modifiable risk factors include dehydration, uncontrolled sepsis, inappropriate use of nephrotoxic medications, major surgery (especially cardiac and orthopedic), radiocontrast exposure, and delayed recognition of early signs. Non-modifiable risks include advanced age, female sex (in some cohorts), and genetic susceptibility variants (e.g., APOL1 in high-risk populations). Beyond mortality—where Stage 3 AKI carries up to 50% in-hospital death risk—AKI profoundly impairs quality of life: survivors frequently experience persistent fatigue, cognitive slowing, depression, reduced physical endurance, and diminished return-to-work rates. Up to 40% develop new-onset or accelerated CKD within one year, increasing long-term cardiovascular morbidity and dialysis dependence. Early detection via serial creatinine monitoring and urine output tracking remains critical; biomarkers like NGAL and TIMP-2•IGFBP7 show promise for preclinical prediction but are not yet routine in standard practice. Multidisciplinary management—including nephrology consultation within 24 hours of diagnosis—is associated with significantly improved outcomes, underscoring the vital role of dedicated renal medicine services.

Acute Kidney Injury (AKI) is a sudden decline in glomerular filtration rate (GFR) occurring over hours to days, characterized by accumulation of nitrogenous waste products (e.g., serum creatinine, blood urea nitrogen), electrolyte imbalances, and fluid overload. Prompt recognition and intervention are critical to prevent progression to chronic kidney disease or death. Management is stratified according to etiology—prerenal (e.g., hypovolemia, cardiac failure), intrinsic (e.g., acute tubular necrosis, glomerulonephritis, vasculitis, interstitial nephritis), or postrenal (e.g., urinary tract obstruction)—and severity, typically staged using the KDIGO criteria (based on serum creatinine rise and/or urine output). Treatment is multidisciplinary, with nephrology-led care central to optimal outcomes.

Conservative treatment forms the cornerstone of AKI management and must be initiated immediately upon diagnosis. Prerenal AKI mandates rapid volume resuscitation with isotonic crystalloids (e.g., 0.9% saline or balanced solutions such as lactated Ringer’s), guided by hemodynamic assessment (central venous pressure, dynamic parameters like stroke volume variation if available) and avoidance of fluid overload. In cardiorenal syndrome, diuretics (e.g., intravenous furosemide) may be used cautiously with close monitoring of renal perfusion and electrolytes. For intrinsic AKI, supportive measures include strict avoidance of nephrotoxins (e.g., NSAIDs, aminoglycosides, iodinated contrast), correction of hyperkalemia (calcium gluconate for cardiac membrane stabilization, insulin–glucose infusion, sodium polystyrene sulfonate or patiromer, or newer potassium binders like sodium zirconium cyclosilicate), management of metabolic acidosis (sodium bicarbonate only if pH <7.15 and hemodynamically stable), and meticulous fluid balance monitoring. Nutritional support is essential: protein intake should be moderated (0.8–1.0 g/kg/day) to reduce nitrogen load without inducing catabolism; caloric intake must be sufficient (25–30 kcal/kg/day) to preserve lean body mass. Early mobilization and prevention of complications—including deep vein thrombosis (prophylactic enoxaparin unless contraindicated), stress ulcer prophylaxis, and delirium screening—are integral components.

Pharmacologic therapy is etiology-specific. In immune-mediated AKI (e.g., ANCA-associated vasculitis, lupus nephritis, or drug-induced interstitial nephritis), prompt immunosuppression is life- and kidney-saving: high-dose intravenous methylprednisolone (500–1000 mg/day for 3 days), followed by oral prednisone taper, combined with cyclophosphamide or rituximab per consensus guidelines. Antibiotics are indicated for pyelonephritis or sepsis-related AKI, with empiric broad-spectrum coverage adjusted per culture results. Diuretic resistance may necessitate combination therapy (e.g., furosemide plus metolazone), though evidence for improved renal recovery remains limited. Renin-angiotensin-aldosterone system inhibitors (RAASi) should be temporarily withheld during AKI episodes due to risk of hyperkalemia and worsening GFR but may be cautiously reintroduced once recovery is established and electrolytes stabilized. Novel agents remain investigational; while natriuretic peptides (e.g., carperitide) showed promise in early trials, they are not standard-of-care outside select research settings.

Surgical intervention is reserved for specific indications. Relief of urinary obstruction—whether from benign prostatic hyperplasia, ureteral stones, or malignancy—is urgent and often achieved via minimally invasive techniques: ureteral stent placement or percutaneous nephrostomy under ultrasound or fluoroscopic guidance. In cases of retroperitoneal fibrosis or pelvic malignancy causing bilateral obstruction, surgical decompression or tumor debulking may be required. Rarely, surgical nephrectomy is considered for irreversible, infected, or massively hemorrhagic kidneys (e.g., in severe vasculitis with cortical necrosis), though this is exceptional. Vascular surgery may be indicated for renal artery or vein thrombosis when anticoagulation alone is insufficient. Importantly, dialysis access creation (e.g., tunneled catheter or arteriovenous fistula) is procedural rather than therapeutic per se but is indispensable for patients requiring renal replacement therapy (RRT).

China offers distinct advantages in AKI management, particularly through its integrated, high-volume nephrology infrastructure. Over 95% of tertiary hospitals have dedicated nephrology departments equipped with advanced continuous renal replacement therapy (CRRT) platforms, enabling precise hemodynamic control in critically ill patients. Chinese nephrologists demonstrate exceptional expertise in CRRT anticoagulation strategies—including regional citrate anticoagulation (RCA), which reduces bleeding risk and extends filter life—and routinely apply real-time biomarker-guided protocols (e.g., TIMP-2•IGFBP7 testing) for early AKI risk stratification. The national AKI surveillance network (launched 2018) facilitates standardized data collection across >1,200 centers, driving evidence-based protocol refinement. Moreover, China’s robust traditional medicine integration permits adjunctive use of evidence-informed herbal formulations—such as Huangqi (Astragalus membranaceus) extracts in clinical trials showing reduced inflammation and improved tubular repair—under strict pharmacovigilance oversight. Tele-nephrology platforms now extend specialist consultation to rural regions, significantly reducing time-to-intervention.

Recovery advice emphasizes longitudinal follow-up and risk mitigation. Patients discharged after AKI require nephrology follow-up within 2 weeks, with serial serum creatinine, eGFR, and urinalysis at 1, 3, 6, and 12 months to detect incomplete recovery or progression. Blood pressure must be tightly controlled (<130/80 mmHg), preferably with RAASi if tolerated, given their renoprotective effects in residual dysfunction. Lifestyle modifications include sodium restriction (<2 g/day), avoidance of NSAIDs and herbal nephrotoxins (e.g., aristolochic acid-containing herbs), smoking cessation, and annual influenza/pneumococcal vaccination. Patients should be counseled on signs of recurrence (e.g., oliguria, edema, fatigue) and instructed to seek immediate evaluation for acute illness, dehydration, or new medications. Long-term cardiovascular risk assessment is mandatory, as AKI independently increases incident heart failure and mortality. Finally, shared decision-making regarding advance care planning—including goals of care discussions about future RRT—should occur early in recovery for high-risk patients. With timely, comprehensive, and individualized management, up to 70–80% of hospitalized AKI patients achieve full renal recovery; however, even partial recovery confers increased long-term morbidity, underscoring the necessity of sustained, coordinated care.